333361-23-2

Upstream product

• 6793-92-6 p-benzyloxyphenylbromide 
• 90050-59-2 5-bromo-2-methylbenzaldehyde 
• 1610955-26-4 (4-(benzyloxy)phenyl)(5-bromo-2-methylphenyl)methanol 
• 21900-41-4 5-bromo-2-methylbenzoyl?chloride 
• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 106-41-2 4-bromo-phenol 
• 100-39-0 benzyl bromide 

Downstream Products

• 1610955-27-5 (3-(4-(benzyloxy)benzyl)-4-methylphenyl)((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanone 
• 1610955-29-7 (2S,3S,4R,5S,6R)-2-(3-(4-hydroxybenzyl)-4-methylphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1610955-34-4 C₃₁H₃₈O₁₀S 
• 1610955-32-2 4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenoxy)butanoic acid 
• 1610955-35-5 C₃₉H₅₃N₃O₁₀S 
• 1610955-33-3 N-(2-methyl-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenoxy)butanamide 
• 1610955-36-6 1-(4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenoxy)butanamido)cyclopentanecarboxamide 
• 1610955-41-3 C₃₃H₄₃NO₁₀S 
• 1610955-39-9 (2S,3S,4R,5S,6R)-2-(3-(4-(2-aminoethoxy)benzyl)-4-methylphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1610955-40-2 1-(1-hydroxy-2-methylpropan-2-yl)-3-(2-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenoxy)ethyl)urea 
• 1610955-44-6 (2S,3S,4R,5S,6R)-2-(3-(4-(3-(benzyloxy)propoxy)benzyl)-4-methylphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1610955-46-8 C₂₉H₃₆O₉S 
• 1610955-45-7 (2S,3S,4R,5S,6R)-2-(4-methyl-3-(4-(3-((methylsulfonyl)oxy)propoxy)benzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1610955-47-9 C₃₃H₄₅NO₉S 

Relevant academic research and scientific papers

Pharmaceutical application of sodium-glucose cotransporter 1 and 2 inhibitors

The invention relates to sodium-glucose cotransporter 1 and 2 (SGLT1and2) inhibitors, a pharmaceutical synthesis method of compounds comprising the inhibitors and application of the inhibitors in treating metabolic diseases, particularly type-2 diabetes.

GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF

Provided are a glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.

Discovery of LX2761, a sodium-dependent glucose cotransporter 1 (SGLT1) Inhibitor restricted to the intestinal lumen, for the treatment of diabetes

The increasing number of people afflicted with diabetes throughout the world is a major health issue. Inhibitors of the sodiumdependent glucose cotransporters (SGLT) have appeared as viable therapeutics to control blood glucose levels in diabetic patents. Herein we report the discovery of LX2761, a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.

INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1

Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula (I): the various substituents of which are defined herein.